Current Situation Overview
In March 2025, the pharmaceutical compound Necronyl was distributed globally as a promising universal cancer treatment. Within weeks, clinical irregularities were reported in patients including cognitive degradation, unregulated tissue regeneration, and loss of self-awareness.
The pathogen—believed to be a mutation caused by Necronyl's synthetic immune modulation—spreads via exposure to infected blood or bodily fluids. Evidence suggests rapid adaptation and possible airborne mutations under specific conditions.
- Status: GLOBAL PANDEMIC — PHASE 6
- Mortality Rate: Unknown (victims are functionally undead, not deceased)
- Global Spread: Confirmed in 191 countries
- Transmission Method: Blood-borne; bite contact; possible airborne vector under investigation
- Estimated Infected: 4.3 billion (as of Dec 2026)
WHO Emergency Response Measures
- Emergency activation of GOARN and EMT networks
- Containment support through Quarantine Control Zones (QCZ)
- Ceasing non-critical WHO initiatives in infected zones
- Global remote bio-surveillance and mutation tracking
Message from the Director-General
“The Necronyl crisis challenges every principle of global health response. We urge immediate isolation of outbreak vectors and strict adherence to field quarantine. While much has been lost, global cooperation continues.”
— Dr. Elena Mbeki, WHO Director-General
(Broadcast: April 2027)